Kelly L, White S, Stone P C
Palliative Medicine, Surrey and Sussex Healthcare NHS Trust, Surrey, UK.
Ann Oncol. 2007 Aug;18(8):1395-9. doi: 10.1093/annonc/mdm138. Epub 2007 May 19.
The vitamin B(12)/C-reactive protein Index (BCI) has been proposed as a prognostic indicator in patients with advanced cancer. The purpose of this study was to confirm the utility of the BCI in palliative care patients.
Patients with advanced cancer provided a blood specimen for analysis. Demographic and disease-related variables were recorded. Patients were followed up for at least 90 days or until death.
Patients (n = 329) were divided into three groups according to their BCI score. Patients in group 3 (BCI >40,000; median survival 29 days) had a significantly (P < 0.01) worse survival than patients in group 2 (BCI 10,001-40,000; median survival 43 days) and patients in group 1 (BCI < or =10,000; median survival 71 days). However, patients in group 1 did not have a significantly better prognosis than those in group 2 (P = 0.091). The point estimates for 90-day mortality for each of the three risk groups were different from the figures previously reported during the development phase of the BCI (group 1, 58.9% versus 47.2%; group 2, 64.0 versus 72.5%; group 3, 78.9% versus 90.6%).
An elevated BCI (>40,000) predicts poor survival in patients with advanced cancer.
维生素B12/ C反应蛋白指数（BCI）已被提议作为晚期癌症患者的预后指标。本研究的目的是证实BCI在姑息治疗患者中的实用性。
晚期癌症患者提供血样进行分析。记录人口统计学和疾病相关变量。对患者进行至少90天的随访或直至死亡。
根据BCI评分将患者（n = 329）分为三组。第3组患者（BCI> 40,000；中位生存期29天）的生存期明显（P <0.01）差于第2组患者（BCI 10,001 - 40,000；中位生存期43天）和第1组患者（BCI≤10,000；中位生存期71天）。然而，第1组患者的预后并不比第2组患者明显更好（P = 0.091）。三个风险组各自的90天死亡率的点估计值与BCI开发阶段先前报告的数字不同（第1组，58.9%对47.2%；第2组，64.0对72.5%；第3组，78.9%对90.6%）。
BCI升高（> 40,000）预示晚期癌症患者生存期较差。
